Aura Biosciences, Inc. Board of Directors

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmette–guérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Dr. Elisabet de los Pinos Ph.D.

Dr. Elisabet de los Pinos Ph.D.

Founder, CEO, President & Director

Dr. Richard Mountfield Ph.D.

Dr. Richard Mountfield Ph.D.

Senior Vice President of Regulatory Affairs & Quality

Mr. Conor Kilroy

Mr. Conor Kilroy

General Counsel & Secretary

Dr. Anthony Daniels M.D.

Dr. Anthony Daniels M.D.

VP & Therapeutic Area of Head Ocular Oncology

Mr. Patrick Nealon

Mr. Patrick Nealon

Senior Vice President of Clinical Development Operations

Ms. Amy Elazzouzi

Ms. Amy Elazzouzi

Interim Principal Financial Officer & Interim Principal Accounting Officer

Dr. Sabine Brookman-May

Dr. Sabine Brookman-May

Senior VP & Therapeutic Area Head of Urologic Oncology

Dr. Jill J. Hopkins M.D.

Dr. Jill J. Hopkins M.D.

Chief Medical Officer & President of Research and Development

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.